Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival
- Ming Yu Lien
- , Ti Hao Wang
- , Ching Yun Hsieh
- , Ming Hsui Tsai
- , Chun Hung Hua
- , Fu Ming Cheng
- , Wen Hui Chung
- , Chih Hsin Tang
- , Jason Chia-Hsun Hsieh*
*Corresponding author for this work
Research output: Contribution to journal › Journal Article › peer-review
12
Scopus
citations